Περίληψη:
Renal involvement in antiphospholipid syndrome (APS), either primary or systemic lupus erythematosus (SLE)-related APS, includes renal artery stenosis or thrombosis, renal infarction, renal vein thrombosis and a small-vessel vaso-occlusive nephropathy defined as "antiphospholipid antibody (aPL)-associated nephropathy." aPL-associated nephropathy is characterized by acute lesions, thrombotic microangiopathy, and chronic lesions such as fibrous intimal hyperplasia, organizing thrombi with or without recanalization, fibrous occlusions of arteries or arterioles and focal cortical atrophy. Systemic hypertension, hematuria, proteinuria (ranging from mild to nephrotic level) and renal insufficiency represent the major clinical manifestations associated with aPL-associated nephropathy. Similar renal histologic and clinical characteristics have been described among all different groups of patients with positive aPL (primary APS, SLE-related APS, catastrophic APS and SLE/non-APS with positive aPL). In patients with aPL-associated nephropathy lesions in the absence of other causes associated with similar histological characteristics, aPL testing needs to be considered. © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.
Λέξεις-κλειδιά:
anticoagulant therapy; anticoagulation; antiphospholipid syndrome; clinical feature; Conference Paper; disease association; hematuria; human; hypertension; immunosuppressive treatment; kidney artery stenosis; kidney disease; kidney failure; kidney infarction; kidney vein thrombosis; multicenter study (topic); outcome assessment; pathogenesis; prognosis; proteinuria; recanalization; renal artery thrombosis; thrombotic thrombocytopenic purpura; antiphospholipid syndrome; blood; complication; Kidney Diseases, phospholipid antibody, Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Humans; Kidney Diseases; Prognosis
